期刊文献+

非发酵糖革兰阴性杆菌感染的治疗困境与药物选择 被引量:8

原文传递
导出
摘要 近年来,细菌耐药性已成为全球关注的问题。由耐药株引起的院内感染不仅延长患者的住院时间,增加医疗费用,而且危及患者的生命。非发酵糖的革兰阴性杆菌是指不能发酵葡萄糖的一群革兰阴性杆菌的总称。铜绿假单胞菌、鲍曼不动杆菌、嗜麦芽窄食单胞菌、洋葱伯克霍尔德菌是临床最常见的非发酵糖菌,其共同的特征是:(1)广泛存在于医院环境;(2)由于膜渗透障碍而天然耐多种抗菌药物;(3)可引起器械相关性感染。随着抗菌药物的广泛应用,非发酵糖菌的耐药状况也越发严重,许多地区出现泛耐药的铜绿假单胞菌、不动杆菌的暴发,部分患者因“无药可用”而死于感染。与此同时,许多大的制药企业逐渐放弃新抗菌药物的研发,特别是抗革兰阴性杆菌的药物的研发就更少。
作者 王辉
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2008年第10期728-730,共3页 Chinese Journal of Tuberculosis and Respiratory Diseases
  • 相关文献

参考文献12

  • 1Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents ,2007,29 : 630-636.
  • 2Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev, 2006, 19:637-657.
  • 3Dubois V, Arpin C, Melon M, et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aemginosa P12 : efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance. J Clin Microbiol,2001,39 : 2072-2078.
  • 4Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis, 2003, 36:1111-1118.
  • 5Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimierobial-resistant Pseudomonas aeruginosa. Clin Infect Dis,2003, 37 :e154-e100.
  • 6Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multi-resistant Gram- negative bacilli in critically ill patients. Crit Care, 2003,7 : R78- R83.
  • 7Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother ,2004,54 : 566-569.
  • 8Michalapoulos A, Kasiakou SK, Mastora Z, et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to mulidrug- resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care,2005,9 : R53-R59,
  • 9Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilatorassociated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother,2005,49 : 1337- 1339.
  • 10Souli M, Kontopidou FV, Koratzanis E, et al. In vitro activity of tigecycline against multi-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother, 2006, 50: 3166-3169.

同被引文献58

引证文献8

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部